EUVIMEDEUVIMED entdecken
Systematische ÜbersichtOpen Access · CC BY 4.0

Risk Perception of Progressive Multifocal Leukoencephalopathy (PML) With Natalizumab in Patients With Multiple Sclerosis and Neurologists: A Systematic Review

Lachlan Williams, Liza van Eijk, Mike Boggild, Zinat Mohammadpour

Acta Neurologica Scandinavica · 2026-01 · 2026 (1)

DOI: 10.1155/ane/5913143 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Acta Neurologica Scandinavica, online erschienen am 14.11.2026. Verfasst von Lachlan Williams und 3 weiteren Autor:innen. Die Arbeit nennt 68 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Progressive multifocal leukoencephalopathy, a rare but fatal complication of natalizumab use in multiple sclerosis, may influence both patients′ and neurologists′ treatment preferences. Understanding how both groups perceive this risk is essential for shared decision‐making. This review is aimed at systematically exploring the risk perception of PML with natalizumab among patients with MS and neurologists.

Methods

Five electronic databases were searched from inception to mid‐March 2025 to find studies reporting perception, tolerance, acceptance, understanding or anxiety of PML risk with natalizumab in adult patients with MS or neurologists. At least two reviewers independently screened studies, extracted data and appraised study quality. Findings were narratively synthesised.

Results

Thirteen eligible articles comprising 16 studies, including 13 quantitative studies with 7723 patients and two with 165 neurologists, and one qualitative study with 20 patients, were included. Six studies were rated high quality, and 10 were moderate quality. In general, both patients and neurologists perceived PML as a moderate risk. Being positive for the John Cunningham virus was linked to higher perceived risk and increased anxiety among patients. Compared with neurologists, patients were more likely to accept and tolerate higher risks, which was more evident among patients treated with natalizumab than those on other medications.

Conclusion

PML risk with natalizumab was perceived similarly among patients and neurologists. However, patients, especially those treated with natalizumab, exhibited higher thresholds for risk. This highlights the need for improved risk communication between patients and neurologists to acknowledge their preferences and support shared decision‐making.

Zitieren

APA

Williams, L., Eijk, L. V., Boggild, M., & Mohammadpour, Z. (2026). Risk Perception of Progressive Multifocal Leukoencephalopathy (PML) With Natalizumab in Patients With Multiple Sclerosis and Neurologists: A Systematic Review. Acta Neurologica Scandinavica, 2026(1). https://doi.org/10.1155/ane/5913143

Vancouver

Williams L, Eijk LV, Boggild M, Mohammadpour Z. Risk Perception of Progressive Multifocal Leukoencephalopathy (PML) With Natalizumab in Patients With Multiple Sclerosis and Neurologists: A Systematic Review. Acta Neurologica Scandinavica. 2026;2026(1). doi:10.1155/ane/5913143

BibTeX
@article{Williams2026,
  author = {Williams, Lachlan and Eijk, Liza van and Boggild, Mike and Mohammadpour, Zinat},
  title = {Risk Perception of Progressive Multifocal Leukoencephalopathy (PML) With Natalizumab in Patients With Multiple Sclerosis and Neurologists: A Systematic Review},
  journal = {Acta Neurologica Scandinavica},
  year = {2026},
  volume = {2026},
  number = {1},
  doi = {10.1155/ane/5913143}
}
Kostenlos starten →